QuidelOrtho Corporation
QDEL$12.29
$-4.04 (-24.72%)-24.72%
ClosedLoading chart...
IndexN/A
Market Cap0.84B
Enterprise Value4.65B
Income$-0.01B
Sales$0.69B
EmployeesN/A
P/E9.17
P/S0.73
P/B1.03
P/C-23.93
EV/EBITDA-9.53
EV/SalesN/A
EPS (ttm)1.34
EarningsN/A
Gross Margin46.67%
Oper. Margin-33.67%
Profit Margin-41.45%
Volume4.88M
Shs Outstand0.07B
Change-24.72%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.78B | $3.00B | $3.27B | $1.70B | $1.66B | $534.89M | $522.28M | $277.74M |
| Cost of Revenue | $1.50B | $1.50B | $1.33B | $420.30M | $312.81M | $214.09M | $206.57M | $121.60M |
| Gross Profit | $1.29B | $1.49B | $1.94B | $1.28B | $1.35B | $320.81M | $315.71M | $156.14M |
| Gross Margin | 46.23% | 49.85% | 59.28% | 75.26% | 81.17% | 59.98% | 60.45% | 56.22% |
| Operating Expenses | $3.25B | $1.36B | $1.09B | $372.30M | $288.53M | $228.09M | $219.78M | $146.59M |
| Operating Income | $-1.96B | $139.10M | $843.70M | $906.00M | $1.06B | $92.72M | $95.93M | $9.55M |
| Operating Margin | -70.46% | 4.64% | 25.83% | 53.34% | 63.81% | 17.33% | 18.37% | 3.44% |
| Net Income | $-2.05B | $-10.10M | $548.70M | $704.20M | $810.29M | $72.92M | $74.18M | $-8.16M |
| Net Margin | -73.74% | -0.34% | 16.80% | 41.46% | 48.76% | 13.63% | 14.20% | -2.94% |
| EPS (Basic) | $-30.54 | $-0.15 | $9.66 | $16.74 | $19.24 | $1.78 | $1.74 | $-0.24 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $6.42B | $8.56B | $8.86B | $2.43B | $1.87B | $910.87M | $806.37M | $935.25M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.44B | $3.56B | $3.92B | $501.00M | $538.46M | $351.05M | $380.79M | $708.15M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $2.98B | $5.01B | $4.93B | $1.93B | $1.33B | $559.82M | $425.58M | $227.10M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.98B | $5.01B | $4.93B | $1.93B | $1.33B | $559.82M | $425.58M | $227.10M |
| Total Liabilities & Stockholders Equity | $6.42B | $8.56B | $8.86B | $2.43B | $1.87B | $910.87M | $806.37M | $935.25M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-2.05B | $-10.10M | $548.70M | $704.20M | $810.29M | $72.92M | $74.18M | $-8.16M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $83.00M | $280.20M | $885.30M | $805.87M | $629.76M | $134.49M | $136.34M | $27.71M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcriptseekingalpha.com QuidelOrtho Q2 Earnings Call Highlightsmarketbeat.com QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimateszacks.com QuidelOrtho Reports Second Quarter 2026 Financial Resultsprnewswire.com Implied Volatility Surging for QuidelOrtho Stock Optionszacks.com Edgestream Partners L.P. Purchases Shares of 117,888 QuidelOrtho Corporation $QDELdefenseworld.net QuidelOrtho to Report Second Quarter 2026 Financial Resultsgurufocus.com QuidelOrtho to Report Second Quarter 2026 Financial Resultsprnewswire.com
Show 12 more stories
Reasons to Add QuidelOrtho Stock in Your Portfolio for Nowzacks.com Beyond Fentanyl: How the Drug Crisis Is Changingprnewswire.com Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firmgurufocus.com Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firmbusinesswire.com 4 Medical Products Stocks Poised to Win Despite Industry Headwindszacks.com QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)prnewswire.com QuidelOrtho: Too Much Uncertainty Around Earnings Keeping Short-Interest Elevatedseekingalpha.com QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?zacks.com QuidelOrtho Appoints Micah Young as Chief Financial Officerprnewswire.com Reasons to Retain QuidelOrtho Stock in Your Portfolio for Nowzacks.com Is QuidelOrtho Corp (QDEL) a Bargain After 3.3% Drop? GF Value Says Undervaluedgurufocus.com Is the Options Market Predicting a Spike in QuidelOrtho Stock?zacks.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Discover more
You may be interested in